ReviewFrontiers in neuroscience2026
From network hub to therapeutic target: the role of mediodorsal thalamic nucleus in epilepsy.
Review in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mediodorsal thalamic nucleus (MD) is a pivotal hub for cortical functions, characterized by significant heterogeneity in its anatomical connectivity, cytoarchitecture, and function, constituting a complex nucleus composed of multiple functionally specialized subregions. We elaborates on the heterogeneous anatomical connectivity of MD and its crucial role in supporting higher cognitive functions such as working memory, cognitive control, and emotional integration. It then focuses on the multifaceted role of MD within epileptic pathological networks. Substantial evidence indicates that MD in patients with epilepsy exhibits structural atrophy and abnormalities in functional connectivity, with its activity being recruited early during seizures and likely involved in seizure propagation and generalization. However, the therapeutic efficacy of neuromodulation targeting MD, such as deep brain stimulation (DBS), remains contentious, highlighting the current insufficient understanding of its distinct functional subregions and specific pathway mechanisms. Finally, the review discusses the challenges and future directions in translating MD into an effective therapeutic target. It emphasizes that future research must endeavor to elucidate its causal mechanisms within epileptic networks at the subregional level, account for the heterogeneity of seizure onset frequencies, and develop precise intervention strategies targeting specific epileptogenic pathways, thereby advancing novel therapies focused on thalamocortical circuits toward clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.